India Pharma Outlook Team | Monday, 17 August 2026
FDA observation outcomes at Aurobindo Pharma’s Raleigh facility have moved into a new phase after the US regulator classified the site as Voluntary Action Indicated.
The US Food and Drug Administration conducted an inspection and issued a Form 483 containing 11 observations.
The Raleigh facility, operated by Aurolife Pharma LLC, manufactures inhalers, dermatology products and transdermal products.
Aurobindo has now received the Establishment Inspection Report. This closes the inspection and provides regulatory clarity for pending applications involving multiple inhaler products in the US market.
Aurobindo Pharma’s Raleigh manufacturing facility in North Carolina has received a VAI classification from the USFDA following an earlier inspection that produced 11 observations. The facility operates through Aurolife Pharma LLC, a wholly owned step-down subsidiary of Aurobindo Pharma.
The USFDA inspected the Raleigh site between March 24 and April 10, 2025. At the conclusion of the inspection, the regulator issued a Form 483 containing 11 observations. Aurobindo described the observations as procedural in nature and committed to addressing them through corrective and preventive actions.
The latest development changes the regulatory status of the facility. Aurobindo has received the Establishment Inspection Report, which classifies the Raleigh facility as VAI and confirms that the USFDA has concluded and closed the inspection.
Also Read: Why Vaccine Innovation Must Go Beyond Traditional Platforms
The VAI classification indicates that the USFDA identified issues requiring attention but did not determine that regulatory action currently warrants further enforcement against the facility. This distinction matters when assessing the latest FDA observation outcome because the classification does not represent an approval of individual products or a finding that every issue has disappeared.
The closure instead gives Aurobindo greater regulatory clarity around the Raleigh site. The company can continue addressing the identified issues while managing its US operations and product applications. The latest report specifically links the classification to pending applications for multiple inhaler products.
Aurobindo’s earlier regulatory filing also said the company did not expect the observations to create any material impact on its current business operations or existing supplies from the facility.
The Raleigh facility plays an important role in Aurobindo’s US product development and manufacturing activities. The site produces inhalers, dermatology products and transdermal products, giving the FDA observation outcome relevance beyond a routine manufacturing inspection.
The facility’s involvement in inhalation therapies makes the VAI classification particularly relevant to Aurobindo’s pending US applications. The inspection closure now provides a clearer regulatory position for those applications as they move through the US market review process.
The latest development therefore connects three key milestones: the 11 FDA observations, the subsequent VAI classification and the formal closure of the inspection. For Aurobindo, the outcome provides a defined regulatory position for a facility involved in complex pharmaceutical products and pending inhaler applications.
